A-GEHB-1 - GE Healthcare/Amersham Biosciences CodeLink? Human Whole Genome Bioarray
GE Healthcare/Amersham Biosciences CodeLink? Human Whole Genome Bioarray targets most of the known and predictive genes of the human genome as it is described today in the public domain. It is comprised of approximately 55,000 30-mer probes designed to conserved exons across the transcripts of targeted genes. These 55,000 probes represent well annotated, full length, and partial human gene sequences from major public databases. GE Healthcare/Amersham Biosciences CodeLink? Human Whole Genome Bioarray probe sequences were selected from the NCBI UniGene build #165, RefSeq database (January 5, 2004 release) and dbEST database (January 8, 2004 release). Some sequences for design were derived from Incyte LifeSeq? Gold and Foundation databases.
Well-annotated mRNA or coding sequences were chosen to ensure usefulness for a large range of applications in basic research, biotechnology, and drug development. Each sequence was carefully screened to ensure high-quality, specific probe design, and to reduce redundancy of gene targets. All of the probes designed to these sequences were functionally tested, and over 80% were functionally validated against 25 human tissues to ensure best representation of the gene and biologically relevant results.
As a result of their high-quality probe content and design, GE Healthcare/Amersham Biosciences CodeLink? Human Whole Genome Bioarrays are useful for performing differential expression studies of many important biological processes in a single experiment. For instance, they can be used to study unique gene expression profiles at different stages of oncogenesis. These studies help to characterize and understand tumor types and tumor progression for use in drug target identification and personalized medicine. In addition, this bioarray enables the investigation of cell and tissue reactions to their environment from stimulus reception to signal transduction processing and response. This bioarray comprehensively covers cell differentiation, development, apoptosis, and metabolism for drugs and other cellular biomolecules.
Expression profiling of the genes involved in these types of biological processes can be directly applied to target identification, pathway characterization, and drug effect prediction in basic research and drug development.
Randall Lockner (email@example.com)
|All 42 experiments done using A-GEHB-1|